2. 国外Cartesian therapeutics 基于其RNA技术建立了 BCMA -RNA Cell 疗法,目前开展了针对重症肌无力的1/2期临床研究(NCT04146051) 3. 德国埃尔朗根-纽伦堡大学(Friedrich-Alexander-Universität Erlangen-Nürnberg 在新英格兰医学杂志报道了一例SLE使用CD19 CAR-T...
2.Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA DOI: 10.1172/JCI130562
Targeting Moiety Peptide Epitope Complexes Having a Plurality of T-Cell EpitopesA variety of targeting moiety peptide epitope complexes (TPECs) are described in different embodiments. In each of the embodiments, however, a targeting moiety may be used to deliver the TPEC to an area of unwanted ...
Unlike chimeric antigen receptors, T-cell receptors (TCRs) can recognize intracellular targets presented on human leukocyte antigen (HLA) molecules. Here we demonstrate that T cells expressing TCRs specific for peptides from the intracellular lymphoid
2023年10月17日,上海药物所李亚平团队与上海科技大学张鹏程团队联合在Advanced Materials上发表了题为“Inhibiting endothelial cell-mediated T lymphocyte apoptosis with integrin-targeting peptide-drug conjugate filaments for chemoimmunotherapy of triple-negative breast cancer”的研究论文 ...
Altered peptide antigens that enhance T-cell immunogenicity have been used to improve peptide-based vaccination for a range of diseases. Although this strategy can prime T-cell responses of greater magnitude, the efficacy of constituent T-cell clonotypes within the primed population can be poor. ...
TCR(T cell receptor)是T细胞表面的特异性受体,以非共价键与CD3结合,形成TCR-CD3复合物,通过识别并结合MHC呈递的抗原从而激活T细胞,促进T细胞的分裂与分化。TCR-T疗法是向正常外周血淋巴细胞上导入已知的抗原特异性TCR基因进行治疗的一种疗法。普通T细胞中引...
15a), CAR-T cells targeting BCMA have demonstrated high MM cell lysis capabilities. The cytolytic activity results showed that compared with other groups, the Bi-CAR-T cells had the highest cytolytic activity in vitro. When the ratio of Bi-CAR-T cell: MM cell was 5:1, 87.3% of target...
TCR(T cell receptor)是T细胞表面的特异性受体,以非共价键与CD3结合,形成TCR-CD3复合物,通过识别并结合MHC呈递的抗原从而激活T细胞,促进T细胞的分裂与分化。TCR-T疗法是向正常外周血淋巴细胞上导入已知的抗原特异性TCR基因进行治疗的一种疗法。普通T细胞中引入新的基因,使得改造过的T细胞能够表达有效识别肿瘤细胞的TCR...
In this study, we developed a novel adoptive T-cell therapy for ovarian cancer based on a chimeric antigen receptor structure. We used a ligand-receptor binding motif to enhance the therapeutic effect of targeting CA125. Since mesothelin can naturally bind to CA125 with high affinity, we concat...